financetom
Business
financetom
/
Business
/
Vail Resorts Visits, Earnings in 2026 Seen Falling on Weak Snowfall, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vail Resorts Visits, Earnings in 2026 Seen Falling on Weak Snowfall, Morgan Stanley Says
Mar 12, 2026 8:31 AM

11:00 AM EDT, 03/12/2026 (MT Newswires) -- Vail Resorts ( MTN ) is expected to see lower earnings and fewer visits this year due to poor snowfall in the Rocky Mountains, though recovery is expected in 2027, Morgan Stanley said in a note Thursday.

The bank said it is lowering its 2026 earnings forecast for the company to $4.77 per share from $6.40, citing poor snowfall in the Rockies, where snowfall was down 43% year over year. The weak conditions reduced Q2 resort visits by 13%. Similar pressure is expected in Q3 if weather conditions remain the same.

Earnings are projected to recover in 2027, helped by more normal weather, higher visitor numbers, and benefits from the company's efficiency initiatives, Morgan Stanley said, adding that it expects resort earnings before interest, taxes, depreciation, and amortization in 2027 to be about 3% higher than 2025 levels.

"As such, we expect the stock to remain range-bound until investors get greater confidence in a credible path to stabilizing and growing Resort EBITDA," the bank said, adding that it is looking forward to the company's March 17 annual analyst day, the first investor event since Rob Katz returned as chief executive officer. Management is expected to provide more detail on the company's long-term growth strategy.

Morgan Stanley adjusted its price target on Vail Resorts ( MTN ) to $147 from $151 and kept its equalweight rating.

Price: 140.26, Change: +1.73, Percent Change: +1.25

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Siemens files lawsuit in Texas against Citgo Petroleum parent
Siemens files lawsuit in Texas against Citgo Petroleum parent
Oct 10, 2024
HOUSTON, Oct 9 (Reuters) - Siemens Energy Inc has filed a lawsuit in a Texas court against Citgo Petroleum's parent, PDV Holding, seeking to recoup about $200 million from a promissory note defaulted by Venezuela, according to a court document seen on Wednesday. Creditors that are part of an auction of Citgo parent's shares in a Delaware court to pay...
Amazon.com to Roll Out AI-Based Delivery Solution by Early 2025
Amazon.com to Roll Out AI-Based Delivery Solution by Early 2025
Oct 10, 2024
11:13 AM EDT, 10/09/2024 (MT Newswires) -- Amazon.com ( AMZN ) said Wednesday that it will roll out its artificial intellgence backed Vision-Assisted Package Retrieval to 1,000 electric delivery vans made by Rivian Automotive ( RIVN ) by early 2025. The company said VAPR uses Amazon Robotics Identification, a computer vision technology, that allows for the automatic identification of a...
Update: Bird Construction Up 14% to a Record as it Boosts Dividend 50% and Releases 2025-2027 Financial Targets
Update: Bird Construction Up 14% to a Record as it Boosts Dividend 50% and Releases 2025-2027 Financial Targets
Oct 10, 2024
11:12 AM EDT, 10/09/2024 (MT Newswires) -- (Updates with analyst comment.) Bird Construction (BDT.TO) was up 14% to a record high after the company on Wednesday raised its dividend by 50% following approval of the company's 2025-2027 strategic plan. The board approved a $0.0233 increase in its monthly dividend to $0.07 per share, an annual dividend rate of $0.84 per...
Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today
Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today
Oct 10, 2024
Inhibikase Therapeutics Inc ( IKT ) shares are trading higher by 31.1% to $1.56 during Wednesday’s session after the company announced the pricing of an approximately $110 million private placement financing. What Else: Inhibikase says the funds will support a Phase 2b trial for pulmonary arterial hypertension (PAH) and general corporate needs. Led by Soleus Capital and joined by investors such as...
Copyright 2023-2026 - www.financetom.com All Rights Reserved